Desmoid tumor study: just watching may be enough

NCT ID NCT04281381

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 100 people with desmoid-type fibromatosis, a rare tumor, for 12 months without giving any treatment. The goal is to see how often the tumors stay stable or shrink on their own. Participants get regular MRI or CT scans to track changes. The results could help doctors decide when to treat and when to simply watch.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could show that many desmoid tumors grow slowly or stay stable, helping doctors avoid unnecessary treatments.

What could go wrong

This is an observational study with no treatment given, so it won't directly help participants. It may also find that some tumors grow quickly, requiring intervention.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DESMOID FIBROMATOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

desmoid tumor fibroma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-••••